The inclusion criteria of insulin bioequivalence trials should emphasize on healthy male volunteers of normal weight aged 18–45 years; those with a BMI of 19–24 kg/m2; those without diabetes, insulin resistance and family history of diabetes; those without cardiovascular disease; and those who had no abnormalities in blood routine examinations, hepatic, and renal function tests. The gene discussed is INS; the disease is cardiovascular disorder.